FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma

On March 15, the FDA’s Oncologic Drugs Advisory Committee will meet to discuss two CAR T cell therapies for multiple myeloma—Abecma, from Bristol Myers Squibb and 2seventy bio, and Carvykti, from Johnson & Johnson and Legend Biotech. Both treatments are currently approved for the treatment of adults with relapsed/refractory multiple myeloma (RRMM) after four or more prior lines of therapy, and their makers are seeking to move them into earlier lines of treatment.